Table 1 Patient characteristics

Median age, range (years)*

69, 56-86

67, 57-79

73, 56-86

Median age at first cancer diagnosis, range (years)

68, 53-80

67, 57-79

68, 53-80

Median ECOG PS, range*

1, 0-2

1, 0-2

1, 0-2

Median interval, range (months)

22, 0-159

0

51, 5-159

Median PSA doubling time, range (months)*

Not applicable

Not applicable

2.5, 1-8

Median PSA, range (μg/L)*

49, 3.9-10,302

173, 12-10,302

23, 3.9-727

Median Hb, range (g/dL)*

13.7, 10.0-16.8

13.9, 10.0-16.8

13.4, 10.2-15.2

Median ALP, range (U/L)*

118, 44-2742

184, 56-2742

102, 44-641

Median LDH, range (U/L)*

206, 158-784

357, 190-784

196, 158-781

Hypo- or hypercalcemia*

0

0

0

Bone pain*

30

11

19

49%

48%

50%

Gleason score < 7, 7, >7**

6, 11, 27

2, 5, 11

4, 6, 16

14%, 25%, 61%

11%, 28%, 61%

15%, 23%, 62%

Other distant metastases*

19

8

11

31%

35%

29%

≤10 bone metastases, >10,

26, 29, 6

6, 12, 5

20, 17, 1

superscan

43%, 48%, 10%

26%, 52%, 22%

53%, 45%, 3%

Initial prostatectomy or radical

10

0

10

radiotherapy

16%

26%

Taxotere treatment

29

12

17

48%

52%

45%

Zoledronic acid treatment

44

18

26

72%

78%

68%

Radioisotope treatment

8

5

3

13%

22%

8%

Alive at the time of analysis

34

14

20

56%

61%

53%

Median follow-up of living patients, range (months)

25, 6-84

29, 9-84

23, 6-67